0001209191-19-023681.txt : 20190404
0001209191-19-023681.hdr.sgml : 20190404
20190404171111
ACCESSION NUMBER: 0001209191-19-023681
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190402
FILED AS OF DATE: 20190404
DATE AS OF CHANGE: 20190404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PENHOET EDWARD
CENTRAL INDEX KEY: 0001198332
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36561
FILM NUMBER: 19732875
MAIL ADDRESS:
STREET 1: ONE EMBARCADERO CENTER SUITE 3700
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNE DESIGN CORP.
CENTRAL INDEX KEY: 0001437786
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262007174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1616 EASTLAKE AVENUE E.
STREET 2: SUITE 310
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: (650) 392-8350
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD
STREET 2: SUITE 250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Immune Design Corp.
DATE OF NAME CHANGE: 20090702
FORMER COMPANY:
FORMER CONFORMED NAME: VACCSYS INC
DATE OF NAME CHANGE: 20080617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-02
0
0001437786
IMMUNE DESIGN CORP.
IMDZ
0001198332
PENHOET EDWARD
C/O IMMUNE DESIGN CORP.
1616 EASTLAKE AVE. E., SUITE 310
SEATTLE
WA
98102
1
0
0
0
Stock Option (Rt to Buy)
1.48
2019-04-02
4
D
0
3058
D
Common Stock
3058
0
D
Stock Option (Rt to Buy)
1.23
2019-04-02
4
D
0
4281
D
Common Stock
4281
0
D
Stock Option (Rt to Buy)
5.60
2019-04-02
4
D
0
10000
D
Common Stock
10000
0
D
Stock Option (Rt to Buy)
4.05
2019-04-02
4
D
0
12500
D
Common Stock
12500
0
D
Stock Option (Rt to Buy)
1.31
2019-04-02
4
D
0
12500
D
Common Stock
12500
0
D
Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding.
Not Applicable.
/s/ Stephen R. Brady, Attorney-In-Fact
2019-04-04